Very excited to share our latest research on immunological features of #LongCovid. Our 2+ year collaboration with @PutrinoLab with many other fantastic colleagues and patients - Mount Sinai Yale Long COVID (MY-LC) study by @sneakyvirus1 et al. 🧵(1/)
There are multiple hypotheses behind long COVID pathogenesis including persistent virus/viral remnants, autoimmunity, dysbiosis, virome reactivation and tissue damage. Our data will dive deep into some of these. (3/)
This is a cross-sectional multi-dimensional immune phenotyping & patient surveys in people with or without LC, who got COVID during the 2020 first wave, on average more than a year from infection. Most were not-hospitalized, ♀ dominant, younger to middle age. (4/)
Long COVID group reported significant increases in the intensity of symptoms and dramatically worsened quality of life. Survey outcomes put together into a single classification metric “Long COVID Propensity Score or LCPS” demonstrated significant diagnostic potential. (5/)
Long COVID participants reported a number of symptoms, most commonly fatigue, brain fog, dysautonomia..etc. Hierarchical clustering of binary symptom data identified 3 clusters of patients with similar sets of self-reported symptoms. (6/)
Next, flow cytometry analysis @peowenlu of peripheral blood mononuclear cells revealed several key differences in LC vs. CC or HC. First, LC had increase in non-conventional monocytes, activated B cells double-negative B cells, and decrease in conventional dendritic cells 1. (7/)
Long COVID participants also had reduced central memory T cells and increased exhausted CD4 and CD8 T cells. The exhausted T cells suggest chronic antigens stimulating these T cells. What they are we do not know yet. (8/)
Long COVID patients also had increases in CD4 T cells that secrete IL-2, IL-4 and IL-6, as well as some that secrete both IL-4 and IL-6. These T cells correlated with the levels of EBV reactive antibodies. Follow me down this thread further to find out more! (9/)
We measured antibody levels against SARS-CoV-2 antigens in people who received 2 doses of mRNA vaccines. Curiously, long COVID patients produced higher levels of IgG against Spike. Without vaccines, LC had higher IgG against nucleocapsid. Data suggest persistent antigen? (10/)
Not only did LC have higher levels of IgG against Spike, but also had IgG against distinct epitopes within the Spike protein, identified by @S_Tabachnikova with @serimmune Kathy Kamath. See the distinct peaks in purple vs. controls. (11/)
Next we examined a large number of plasma factors and asked which factors are most different in long COVID vs. non-long COVID groups. By far the most significant differences were found in cortisol levels. Long COVID group had lower plasma cortisol levels than control groups.(12/)
Cortisol levels in circulation were about half of the control groups. Despite this, we saw no elevation in ACTH levels, suggesting an impaired compensatory response by the hypothalamic-pituitary axis. (13/)
This is so interesting, giving the report by @SuYapeng et al showing similar reduction in long haulers with respiratory viral symptoms at 2-3 months post COVID. This implies chronic hypocortisolism in long COVID. (14/)
What about autoantibodies? @_BlueJay3 and @aaronmring used Rapid Extracellular Antigen Profiling (REAP) version 2.0 (with more antigens added) to examine autoantibodies. In contrast to what we found for acute severe COVID, long COVID group did not have elevated AABs. (15/)
However, REAP did find notably elevated autoantibodies to sodium ion transporters in a subset of Long COVID patients who displayed reactivities agains 6-9 different proteins of this family. Those with tinnitus and nausea had elevated levels of these AABs. (16/)
In contrast to autoantibodies, REAP detected elevation in IgG against herpesvirus antigens. In particular, antibody reactivity to glycoproteins and early antigens of Epstein-Barr virus, Varicella zoster virus were elevated in long COVID over other groups. (17/)
The increases in antibodies to EBV and VZV antigens were also detected using independent assays like ELISA and @serimmune epitope mapping. However, seroprevalence for EBV and VZV were similar in LC and CC. These data suggest recent reactivation of EBV and VZV in LC. (18/)
This again is consistent with the report by @SuYapeng et al, showing that EBV viremia at the time of diagnosis is one of the four predictive factors for long COVID. (Note that our study did not examine viremia but infer EBV reactivation by serology)(19/)
Notably, these anti-EBV antibodies found in LC correlated with the levels of IL-4/IL-6 double-positive CD4 T cells I mentioned above. Significant correlations were also found between EBV p23 reactivity and terminally differentiated effector memory (TEMRA) CD4 T. (20/)
Finally @rahuldhodapkar used machine learning and found that immune features alone can predict long COVID with efficient discriminative performance (AUC=0.96)! The most informative individual data blocks contributing to efficient separation of groups are flow and cytokine. (21/)
Several features significantly distinguished Long COVID (double negative B cells, serum galectin-1, various EBV epitopes) while others were negatively associated (serum cortisol, PD-1+ CD4+ TCM, and HSV1 and HSV2 motifs). (22/)
In fact, serum cortisol was the most significant individual predictor of Long COVID status in the model, and alone was a predictor wit an AUC of 0.96 (95% CI: 0.92-0.99). Notably, serum cortisol within the MY-LC study was highest in HC > CC > LC. (23/)
We found many key circulating biological factors that alone can discriminate long COVID from others. Comparison of classification accuracies between patient reported outcomes and machine learning revealed substantial agreement (Cohen’s Kappa .865, 95% CI [0.83 - .90]). (24/)
While we are so excited about the findings of this study, we also wish to highlight key limitations of this study. They are summarized here but there may be more. Our study is exploratory in nature and requires validation. (25/)
Here is the summary of our findings. There are many implications for diagnosis and therapy for #longCOVID. (26/)
For example, can we target viral reservoir with antivirals and mAbs? Can we restore cortisol levels? Should therapy be targeting EBV? Would immunomodulatory therapy against inflammatory cytokines be useful? We still need to identify long COVID endotypes for treatment. (27/)
We hope that our study will be informative to others working in the field. We need validation across cohorts. We also hope that these data will help those who are still skeptical understand that long COVID is real, and it has biological basis. Thank you for reading. (End)
And I finally got to meet @PutrinoLab in person after a million zoom meetings and phone calls. How amazing to have a collaborator who is also a great friend!! 😊
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Happy to share our latest work by @YYexin et al. on antibody-mediated control of endogenous retroviruses in mice. In the process, we found “natural antibodies” with broad reactivity against enveloped viruses. Here is how “panviral” antibodies work 🧵(1/)
Endogenous retroviruses (ERV) are remnants of genetic invaders that have integrated into our ancestors' genomes over millions of years. ERVs occupy ~8% of the human genome and are under constant host immune surveillance. (2/) nature.com/articles/nrg31… nature.com/articles/nrmic…
This work started over 7 years ago when @YYexin and @rebecca_treger began to examine why ERVs reactivate in certain mouse strains. Through many genetic crosses, we figured out that secreted IgM recruits complement to suppress infectious ERV from emerging. (3/)
This time, we developed a nasal booster vaccine for influenza viruses. In this preprint, @MiyuMoriyama et al. show that nasal boosters with unadjuvanted hemagglutinin protein induce sterilizing immunity in mice against flu. (1/) biorxiv.org/content/10.110…
This work builds on the Prime and Spike vaccine strategy by @tianyangmao @BenIsraelow et al. against COVID where mRNA vaccine followed by nasal booster with recombinant spike protein established local immunity, ⬇️ infection & transmission in rodents. (2/) science.org/doi/10.1126/sc…
For Prime and HA against flu, @MiyuMoriyama tested several different mRNA IM prime and nasal HA booster doses, followed by a homologous influenza virus challenge. Like Prime and Spike, no adjuvant is needed for the nasal booster due to preexisting immunity from Prime. (3/)
Much-needed data on the genetics of #longCOVID in a new preprint by @23andMeResearch - GWAS of #LongCOVID identified 3 loci pointing to immune and thrombo-inflammatory mechanisms 🔥 @ninaadsc 1) HLA-DQA1–HLA-DQB 2) ABO 3) BPTF–KPAN2–C17orf58
(1/) medrxiv.org/content/10.110…
Among research participants who reported acute SARS-CoV2 infection, 64,384 participants reported to have experienced Long COVID and 178,537 participants did not. Their analytical cohort consisted of 54,390 cases and 124,777 controls 👇🏼 (2/)
The top locus was in the HLA-DQA1–HLA-DQB intergenic region. Further analysis showed that HLA alleles HLA-DRB1*11:04, HLA-C*07:01, HLA-B*08:01, and HLA-DQA1*03:01 were significantly associated with #LongCOVID. In other words, crucial genes for T cell target detection! (3/)
Keynote talk by @MichaelPelusoMD. “#LongCovid is not a mystery anymore. Working with patients, I have optimism that we can figure this out.” #YaleCIISymposium
An excellent framework in thinking about the pathogenesis of #LongCovid
@MichaelPelusoMD
Sharing this scoping review on "Post-Acute sequelae of COVID-19 in pediatric patients within the United States" by @ChrisMillerDO - an amazing @YalePediatrics infectious diseases fellow focused on research and treatment of #longcovidkids (1/)
Key findings:
- Most pediatric LC patients were adolescents.
- ♀>♂️
- 80% of pediatric LC patients started with a mild initial infection.
- Asthma, atopy, allergic rhinitis (type 2 immune diseases), and obesity were frequently reported pre-existing conditions. (2/)
The most frequently reported symptoms in #longcovidkids are listed here (3/)
An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/) nature.com/articles/s4159…
The longevity of antibody-mediated protection against infectious diseases rely on whether or not the vaccines can establish long lived plasma cells (LLPC) in the bone marrow. They are the source of circulating antibodies for years to decades. (2/) nature.com/articles/s4159…
The study by Nguyen et al examined the long lived and short lived plasma cells in the bone marrow in people who received COVID mRNA vaccines, tetanus and flu vaccines at various time points . They found no LLPC (PopD) specific to COVID but found PopD against tetanus and flu. (3/)